# A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

> **NCT07515469** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Iparomlimab and Tuvonralimab Injection
- Neoadjuvant Immunotherapy

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab

## Key facts

- **NCT ID:** NCT07515469
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2028-05-30
- **Final completion:** 2030-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07515469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07515469, "A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07515469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*